Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Summary

This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2022-01-23

Primary completion

2026-05-13

Completion

2026-05-13

Outcome

Outcome not reported

Stopped (Business): “Study ended earlier than anticipated due to end of funding.”

Drugs

Indications